Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.47 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.47 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31735948 | 0.87 | CYP19A1 (0.54) | MAPTLMNANOS1GRIA1GRIA2 | |
| SCHEMBL1465120 | 0.87 | CYP19A1 (0.54) | MAPTLMNANOS1GRIA1GRIA2 | |
| SCHEMBL1630724 | 0.78 | MAPT (0.51) | MAPTLMNACYP3A4ALOX15NOS1 | |
| SCHEMBL28556734 | 0.77 | NPBWR1 (0.45) | MAPTLMNACYP3A4ALOX15NOS1 | |
| SCHEMBL5150341 | 0.75 | MAPT (0.51) | MAPTLMNACYP3A4ALOX15NOS1 | |
| SCHEMBL4969287 | 0.75 | MAPT (0.51) | MAPTLMNACYP3A4ALOX15NOS1 | |
| SCHEMBL9053698 | 0.74 | NPBWR1 (0.52) | MAPTLMNACYP3A4ALOX15NOS1 | |
| SCHEMBL397170 | 0.74 | ALDH1A1 (0.56) | MAPTLMNACYP3A4ALOX15NOS1 | |
| SCHEMBL7968898 | 0.73 | CYP19A1 (0.49) | MAPTLMNANOS1GRIA1GRIA2 | |
| SCHEMBL3962934 | 0.73 | CYP19A1 (0.49) | MAPTLMNANOS1GRIA1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005287-A2 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20130338158-A1 | 6-SUBSTITUTED INDOLE-3-CARBOXYLIC ACID AMIDE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8524917-B2 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524917-B2 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524917-B2 | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity | ALLERGAN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | ALLERGAN, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | ALLERGAN, INC. | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171772-A1 | e.g. Methyl 1-Benzyl-6-methoxy-1H-indole-2-carboxylate; glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, wound healing, platelet aggregation and thrombosis | PTGIR, S1PR1, TBXA2R | MAPT 4739/4885LMNA 3042/4885CYP3A4 1490/4885 |
| US-20150005287-A2 | QUINOLONE COMPOUND | HAX1, NQO2, VIP | MAPT 4586/4885LMNA 4065/4885CYP3A4 219/4885 |
| US-20130338158-A1 | 6-SUBSTITUTED INDOLE-3-CARBOXYLIC ACID AMIDE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY | S1PR1, S1PR3, S1PR2 | MAPT 4437/4885LMNA 2882/4885CYP3A4 2666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.